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Stromal Fibroblast–Specific Expression of ADAM-9
Modulates Proliferation and Apoptosis in
Melanoma Cells In Vitro and In Vivo
Anna N. Abety1, Jay W. Fox2, Alexander Scho¨nefuß1, Jan Zamek1, Jenny Landsberg3,
Thomas Krieg1, Carl Blobel4, Cornelia Mauch1 and Paola Zigrino1
ADAMs are members of the zinc metalloproteinase superfamily characterized by the presence of disintegrin
and metalloprotease domains. In human melanoma, ADAM-9 is expressed in focalized areas of the
tumor–stroma border in both melanoma and stromal cells. However, the role of ADAM-9 in melanoma
progression remains elusive. To analyze the role of stromal-derived ADAM-9 for the growth and survival of
melanoma cells, we have used in vitro coculture systems of melanoma cells and ADAM-9/ fibroblasts.
Coculture of melanoma cells in the presence of ADAM-9/ fibroblasts led to increased melanoma cell
proliferation and reduced apoptosis as compared with control cocultures. We identified TIMP-1 and sTNFRI as
the two relevant factors expressed in increased amounts in culture supernatants from ADAM-9/ fibroblasts.
TIMP-1 was associated with induced melanoma cell proliferation, whereas soluble TNFR1 mediated the reduced
cellular apoptosis in vitro. In vivo, injection of murine melanoma cells into the flank of ADAM-9/ animals
resulted in the development of significantly larger tumors than in wild-type animals as a result of increased
proliferation and decreased apoptosis of melanoma cells. Taken together, stromal expression of ADAM-9 during
melanoma development modulates the expression of TIMP-1 and sTNFR1, which in turn affect tumor cell
proliferation and apoptosis.
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INTRODUCTION
Development of melanoma is typically initiated in the skin
and is frequently followed by recurrence at distant sites.
This process involves expression and activity of proteolytic
enzymes to degrade basement membranes, migration
through the tissue, and modulation of cellular contacts.
Enzymes involved in these processes belong to the metallo-,
serine, and cysteine proteases produced by either melanoma
cells or stromal cells surrounding the tumor, or both (Zigrino
et al., 2005a). A family of proteases with a disintegrin and
metalloprotease domain (ADAM) has been involved in
cancer progression (Duffy et al., 2009). ADAMs shed cell
surface molecules having important roles in cancer progres-
sion such as TNFR, EFGR, and their ligands (Murphy, 2008).
Among those enzymes, ADAM-9 is upregulated in a number
of cancers including renal, breast, and prostate cancer
(O’Shea et al., 2003; Fritzsche et al., 2008). In prostate
cancer, ADAM-9 leads to altered FGF and EFG signaling by
cleaving the FGFR2iiib and EGF ligands (Peduto et al., 2005).
A further activity ascribed to ADAMs is their ability to
mediate cellular interactions with integrin receptors (White,
2003). ADAM-9 has been shown to interact with a6b1 on
fibrosarcoma cells (Nath et al., 2000) and with a3b1 integrins
on keratinocytes (Zigrino et al., 2007), thereby modulating cell
migration. ADAM-9 is also upregulated in human melanoma,
where its expression is detected at the tumor–stroma border
by both tumor and stromal cells (Zigrino et al., 2005b). In
melanoma cells, we have recently shown that ADAM-9 interacts
with multiple b1 integrin receptors to mediate interaction
with stromal fibroblasts in vitro (Zigrino et al., 2011).
Despite the above data, the precise role of host-derived
expression of ADAM-9 for the progression and metastasis of
melanoma is unclear. To address this question, we used
both in vitro coculture system of B16F1 melanoma cells and
wild-type (WT) or ADAM-9 null fibroblasts (ADAM-9/)
and in vivo grafting of murine melanoma cells in animals
with genetic ablation of ADAM-9. We provide evidence that
two factors , TIMP-1 and soluble TNFR1, are altered upon
ADAM-9 ablation and mediate increased proliferation and
reduced apoptosis, respectively, in melanoma cells in vitro
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and in vivo. In summary, we have identified ADAM-9 with
a role in modulating the proliferation and apoptosis
of melanoma cells.
RESULTS
ADAM-9 expression in stromal fibroblasts modulates
melanoma cell growth
In murine melanomas, as shown in Figure 1a, ADAM-9 was
expressed similarly as observed in human tumors, with
ADAM-9 detected in melanoma cells facing the stroma and
in peritumoral stromal cells. In vitro, coculture of B16F1
murine melanoma cells either in transwell or with condi-
tioned media (CM) prepared from WT or ADAM-9/
fibroblasts resulted in a significant increase of proliferation
when cultured with ADAM-9/ as compared with WT
fibroblasts (Figure 1b). A similar pro-proliferative effect of
ADAM-9/ fibroblast media was detected in BLM, A375,
and 530, but not in SKmel28 human melanoma cells
(Supplementary Figure 1A online). Interestingly, no altered
cell proliferation was detected when other tumor cells, such
as glioma (Gli36) or the tumorigenic keratinocyte line (II4rT),
were stimulated with CM from both fibroblast genotypes
(Supplementary Figure 1A online).
These results indicated that increased melanoma cell
proliferation is induced by a soluble factor–mediated
mechanism. To identify the soluble factors secreted by
fibroblasts that could influence B16F1 melanoma cell
proliferation, supernatants from WT and ADAM-9/ fibro-
blast were analyzed by a mouse cytokine antibody array.
A prominent increase of TIMP-1, sTNF-a, and sTNFRI in
supernatants from ADAM-9/ fibroblasts was observed
compared with WT fibroblasts (Figure 2a).
Increased expression of TIMP-1 was also detected in
supernatants of ADAM-9/ fibroblasts analyzed by immu-
noblot; one representative culture is shown for each genotype
(Figure 2b). In addition, semiquantitative reverse transcriptase
PCR analysis of TIMP-1 from ADAM-9/ and WT fibroblasts
showed increased TIMP-1 transcript levels in ADAM-9/
versus WT fibroblasts (Figure 2b).
ELISA results showed an increase of intracellular and
secreted tumor necrosis factor (TNF)-a in ADAM-9/ as
compared with WT fibroblasts (Figure 2c). By western blot
analysis, we could also detect increased amounts of soluble
TNFRI in the supernatant from ADAM-9/ fibroblasts
(Figure 2d). Two forms were identified, the 55-KDa,
exosome-associated TNFRI (ex-TNFRI) (Feras et al., 2004)
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Figure 1. ADAM-9 expression in murine melanoma. (a) ADAM-9 detection
in B16F1 melanomas grown in mice. ADAM-9 expression in melanoma at the
tumor–stroma border is indicated by the arrow. IgGs were used as control.
Dashed lines denote the tumor–stroma border. s, stroma; t, tumor. Scale
bar¼ 200 mm. (b) B16F1 proliferation after coculture with wild-type (WT) or
ADAM-9/ fibroblasts either in transwell or with conditioned media (CM).
The average proliferation of cells cultured with 10% serum (þ ) was set to
100%, and cell proliferation in the presence of WT or ADAM-9/ fibroblasts
or fibroblast CM was calculated as a ratio of this value. Serum-free control is
indicated by (). The graph represents mean±SD. *Po0.05, **Po0.001.
WT
GM-CSF
a
c
b
d
sTNF-α
TNF-α (pg ml–1)
IFNγ
IL-1α
IL-6
sTNFRI
TIMP-1
CRG-2
3.44
0.55
28.59
15.35
6.50
0.57
52.78
4.19
0.61
7.59
2.05
2.00
1.65
1.32
3.61
2.53
ADAM-9–/–
WT
WT
Supernatant
Su
pe
rn
a
ta
nt
Su
pe
rn
a
ta
nt
m
R
N
A
m
R
N
A
34.8 ± 5.9
46.6 ± 6.7
20.2 ± 12.9
55.2 ± 38.3
Lysate
Ly
sa
te
ADAM-9–/–
ADAM-9–/–
WT
TIMP-1
28.5 KDa 
ex-TNFR1
55 KDa
55 KDa
Actin
TNFRI
S26
sTNFR1
28KDa
Ponceau
Ponceau
TNFRI
TIMP-1
S26
ADAM-9–/–
Figure 2. TIMP-1 enhances B16F1 proliferation. (a) Expression of soluble
factors in fibroblast supernatants using a mouse cytokine antibody array. Shown
are arbitrary units/biotin-conjugated IgG-positive control. (b) Analysis of TIMP-1
protein in supernatants from fibroblasts. Ponceau was used to ensure loading/
transfer. Shown is a representative blot (n¼5 per genotype). Reverse
transcriptase PCR (RT–PCR) amplification of the TIMP-1 transcript. Shown is a
representative amplification (n¼8 per genotype). (c) Quantification of tumor
necrosis factor (TNF)-a in fibroblasts by ELISA (n¼ 4 per genotype). Values are
expressed as mean±SD. (d) Analysis of TNFRI in fibroblasts. Shown is one
representative analysis out of two using five different fibroblast preparations
per genotype. Ponceau and actin were used as controls. S26 was used as
internal control for RT–PCR. mRNA, messenger RNA; WT, wild type.
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and the 28-KDa shed form (sTNFRI), with a parallel decrease
of the membrane-bound form (Figure 2d). In addition, no
alteration in TNFRI transcripts was detected in both fibroblast
genotypes (Figure 2d).
TIMP-1 enhances melanoma cell proliferation
Incubation of B16F1 cells with recombinant TIMP-1 for
24 hours resulted in a significant increase in cell proliferation
compared with that under serum-free conditions (Supple-
mentary Figure 1B online). Increased proliferation was also
detected in human melanoma cells stimulated with the
recombinant TIMP-1 (Supplementary Figure 1B online),
suggesting a common mechanism of induction.
To investigate whether increased TIMP-1 detection in
fibroblasts media is responsible for the induction of murine
melanoma cells proliferation in coculture, we neutralized
TIMP-1 in the supernatant from ADAM-9/ fibroblasts
before melanoma treatment. Blocking the activity of TIMP-1
using neutralizing antibodies led to abolishment of the
induced melanoma cell proliferation, which was now
comparable to those detected upon cell stimulation with
the supernatant from WT fibroblasts (Figure 3a).
ADAM-9 depletion in fibroblasts leads to reduced melanoma
cell apoptosis
Stimulation of B16F1 cells with CM from ADAM-9/
fibroblasts resulted not only in a significant increase in
proliferation (Figure 1b) but also in a concomitant reduction
of B16F1 apoptosis compared with cells stimulated with WT
supernatants (Figure 3b). Despite being tumor cells, B16F1
cells treated with TNF undergo the apoptosis process,
indicating that they are still sensitive to apoptosis induction
(Figure 3b). As shown in Figure 3c, neutralization of TIMP-1
in ADAM-9/ fibroblast media had no effect on B16F1
apoptosis, thus excluding TIMP-1 as the factor mediating the
anti-apoptotic effect observed.
Two additional proteins that we found alternatively
secreted/processed in the media of ADAM-9/ fibroblasts,
namely sTNF-a and sTNFRI (Figure 2a, c, and d), have been
shown to exert an important role in apoptotic processes
(Chen and Goeddel, 2002).
To investigate whether blocking sTNFRI release from cell
surface, which we found increased in ADAM-9/ fibroblast
supernatants, would abolish the detected reduced apoptosis
in B16F1, we have treated ADAM-9/ fibroblasts with
TAPI-0, a metalloproteinase inhibitor, before melanoma cell
treatment. TAPI-0 treatment led to efficient inhibition of
TNFRI shedding, and the soluble form of the receptor was
now undetectable in fibroblast supernatants (Figure 4a).
Furthermore, reduced release of TNFRI was paralleled by
increased detection of the membrane-bound form. Stimula-
tion of B16F1 cells with supernatant from TAPI-0-treated
ADAM-9/ fibroblasts led to a significant increase in B16F1
cell apoptosis; this effect could be blocked when, in addition,
we also supplied recombinant soluble TNFRI to the media
(Figure 4a). These results support the antagonistic role of
increased sTNFRI in ADAM-9/ fibroblasts in mediating
suppression of B16F1 apoptosis.
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Figure 3. TIMP-1 influences B16F1 proliferation but not apoptosis. (a) B16F1 cell proliferation in the presence of conditioned media (CM) from fibroblasts with/
without anti-TIMP-1 or IgG control antibodies (2 mgml1, a-TIMP-1). Cell proliferation in the presence of ADAM-9/ supernatant was set as 100%. **Po0.005.
B16F1 cell apoptosis in the presence of c.m. from fibroblasts without (b) or with (c) anti-TIMP-1 or IgG control antibodies (2 mgml1, a-TIMP-1). Values are
expressed as percentage relative to the 100% reference value (cell apoptosis in the presence of 100 ngml1 recombinant TNF-a). *Po0.05; **Po0.008.
All data represent mean±SD, and graphs are representative of three independent experiments. TNF-a, tumor necrosis factor; WT, wild type.
www.jidonline.org 2453
AN Abety et al.
Role of ADAM-9 in Melanoma
Culture of B16F1 cells with supernatant from WT fibro-
blasts in the presence of recombinant soluble TNFRI (Enbrel)
significantly reduced B16F1 cell apoptosis, mimicking the
anti-apoptotic effect of the supernatant from ADAM-9/
fibroblasts on B16F1 cells (Figure 4b).
The release of TNFRI from the cell surface has been shown
to be mainly mediated by the activity of TACE/ADAM-17
(Bell et al., 2007). By reverse transcriptasePCR analysis
of ADAM-17 transcripts in ADAM-9-null fibroblasts, we
detected an B2-fold upregulation as compared with WT
(Figure 4c). Increase in transcripts was paralleled by
increased expression of ADAM-17 protein in both pro
and active forms in lysates of ADAM-9-depleted fibroblasts
as compared with WT cells (Figure 4c).
To support the causal role of ADAM-17, we silenced
ADAM-17 in ADAM-9-null fibroblasts. We obtained efficient
downregulation with the most prominent transcriptional
effect (80%) when using 150 pmol of the small interfering
RNA (Supplementary Figure 3A online). A less prominent,
20%, reduction of pro and active forms of ADAM-17 was
instead detected by immunoblot (Supplementary Figure 3B
online). Silencing of ADAM-17 in ADAM-9/ fibroblasts
also resulted in a 30% reduction in 28-KDa shed TNFR
(Supplementary Figure 3C online), and stimulation of B16F1
cells with supernatant from silenced ADAM-9/ fibroblasts
led to a small but significant increase in B16F1 cell apoptosis
(Supplementary Figure 3D online).
ADAM-9/ ablation in mice results in enhanced melanoma
growth
To translate our in vitro findings in vivo, we analyzed the
growth of B16F1 melanoma cells in WT mice and mice
lacking ADAM-9. B16F1 melanoma cells were injected
intradermally into the flank of WT or ADAM-9/ mice.
Tumor growth/size was measured as a function of time.
Measurable tumors were detected as early as 6 days post
B16F1 injection and reached an average size of 34.3mm3
in WT animals, whereas depletion of ADAM-9 resulted
in significantly increased tumor size up to 4-fold, with an
average size of 131.2mm3 (Figure 5a). At day 13, 42% of
ADAM-9/mice had tumors larger than 1 cm3, in contrast to
the WT mice with only 11% of tumors larger than 1 cm3
(Figure 5a). A similar difference in tumor growth was also
detected when we used B16F0 cells and tumor explants from
the Hgf-Cdk4R24C mice (data not shown; Tormo et al., 2006).
In vivo, analysis of ADAM-9 messenger RNA transcripts in
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B16F1 tumors developed either in WT or ADAM-9/
animals showed increased expression in tumors grown in
the WT and ADAM-9/ hosts as compared with healthy
skin, although this was more abundant in the WT mice
(Supplementary Figure 2 online).
Melanoma cell proliferation in vivo was altered as
indicated by the 2.5-fold increase in the average number of
Ki67-positive cells within the tumors of ADAM-9/ animals
at day 13 post injection as compared with those developed in
WT littermates (Figure 5c, upper panel). Similarly, quantifica-
tion of the number of active caspase-3-positive melanoma
cells in the same specimens showed a significant (2.7-fold)
reduction in the number of apoptotic melanoma cells in
ADAM-9/ animals as compared with WT (Figure 5c).
Analysis of tumor-infiltrating T-/B-cells, neutrophils, and
macrophages showed no significant difference in the infil-
trated cells in melanomas developed in WT or ADAM-9/
mice. We failed to detect any alterations in the number of
vessels formed around the tumors in both animals (data not
shown). These results suggest that increased tumor growth
in ADAM-9/ animals is the result of an altered balance
between proliferation and apoptosis upon tumor–stroma
communication.
Analysis of TIMP-1, sTNF-a, and sTNFRI in extracts from
melanomas by antibody array indicated increased amounts,
similar to those detected in vitro (Figure 2), of all three
proteins in the tumor from ADAM-9/ as compared with WT
mice (Figure 6a). In vivo, we detected increased TIMP-1 in
elongated fibroblast-like cells in the peritumoral stroma,
whereas very little expression was observed in the peritumor-
al stroma of tumors from WT littermates (Figure 6b, lower
panel). Accordingly, increased B16F1 melanoma cell pro-
liferation was also detected in the tumor periphery, facing the
stroma, in tumors from ADAM-9/ (Figure 6b) as compared
with WT mice.
DISCUSSION
ADAM-9 is a multidomain metalloprotease that has been
shown to be upregulated in a number of cancers (O’Shea
et al., 2003; Fritzsche et al., 2008). In melanoma developed
in mice, ADAM-9 expression is observed at the tumor–stroma
border in stromal and tumor cells, an expression pattern that
resembles that observed in primary human melanoma
(Zigrino et al., 2005b). Even though we could show that
ADAM-9 expression by both melanoma cell and stromal
fibroblasts may mediate cellular interactions (Zigrino et al.,
2011), a role for the fibroblast-specific expression of ADAM-9
during melanoma development remained elusive. To analyze
how ADAM-9 expression in fibroblasts influences melanoma
growth, we used in vitro coculture systems of melanoma cells
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and fibroblasts isolated from WT or ADAM-9/ mice.
Interestingly, direct (transwell) or indirect (CM) coculture of
B16F1 cells with ADAM-9/ and WT dermal fibroblasts led
to a significant induction of proliferation, paralleled by a
reduction of apoptotic cells. These data indicated that soluble
factors secreted or released from the cell surface from ADAM-
9/ fibroblasts have the potential to modulate the growth of
melanoma cells. TIMP-1 was among those factors altered in
ADAM-9/ fibroblasts in vitro. Neutralization of TIMP-1
abolished the increased melanoma cell proliferation ob-
served upon stimulation with supernatant from ADAM-9/
fibroblasts. The growth-promoting activity of TIMP-1 was not
only limited to murine melanoma cells but was also found
with human melanoma cells, suggesting that the observed
event may be important also in the context of human disease.
The activity of TIMP-1 in cancer is quite controversial, being
either a promoter (Yoshiji et al., 1998) or an inhibitor of
tumor growth (Soloway et al., 1996). Recent reports demon-
strated that TIMP-1 regulates cell proliferation in colorectal
cancer cells and premalignant melanocytes, although the
molecular mechanisms of this regulation are still not known
(Sorensen et al., 2008; Ricca et al., 2009). Despite the fact that
TIMP-1 also has anti-apoptotic activity (Stetler-Stevenson,
2008), neutralization of TIMP-1 in CM from ADAM-9/
fibroblasts did not affect apoptosis of stimulated melanoma
cells. Two additional factors identified as increased in
ADAM-9/ fibroblast supernatants were TNF-a, a cytokine
that exerts antitumor immunity by binding to TNFRI (Chen
and Goeddel, 2002; Calzascia et al., 2007), and soluble
TNFRI. Binding of soluble TNF-a to soluble TNFRI antag-
onizes binding to the membrane receptor, thus impeding
transduction, leading to apoptosis (Engelmann et al., 1989;
Chen and Goeddel, 2002). We believe that in our system this
mechanism is responsible for the reduced apoptosis detected
in melanoma cells. Soluble TNFRI is released by ectodomain
shedding (Hikita et al., 2009), and ADAM-17 has been
identified as the main sheddase in this process (Bell et al.,
2007). Interestingly, we found ADAM-17 upregulated in
fibroblasts from ADAM-9-null animals, thus suggesting that
the increase in sTNFRI maybe due to the observed increase
in ADAM-17. Downregulation of ADAM-17 by RNA silencing
or inhibition of proteolytic activity with TAPI-0 in ADAM-9/
fibroblasts led to reduced sTNFRI shedding and in turn to
increased apoptosis of stimulated B16F1 cells. Thus, taken
together, we suggest that increased expression and activity
of ADAM-17 may mediate the proteolytic release of
sTNFRI, which binds TNF and leads to decreased B16F1
apoptosis upon stimulation with ADAM-9/ fibroblast
supernatant.
In the absence of ADAM-9, altered production of TIMP-1
and TNF-a may be the result of an altered notch signaling.
One explanation for this may be the persistence of notch
signaling as a result of reduced Delta-Like ligand-1 (Dll-1)
cleavage in the absence of enzymatic activity of ADAM-12
and -9 (Dyczynska et al., 2007; Zolkiewska, 2008).
To analyze the implications for our in vitro finding in vivo,
we grafted B16F1 melanoma cells in the flank of WT and
ADAM-9/ mice. As predicted by the pro-proliferative and
anti-apoptotic effect, which we detected in ADAM-9/
fibroblasts toward B16F1 melanoma cells in vitro, we
observed increased tumor growth in mice lacking ADAM-9.
In line with our in vitro data, also in vivo we detected a
significant increase in tumor cell proliferation in melanoma
developed in ADAM-9/ mice, while apoptosis was
reduced. In addition, in vivo we could detect increased
expression of sTNF-a and sTNFRI in tumors from ADAM-9/
mice. A similar increase was also found in the levels of TIMP-
1, which localizes in fibroblasts at the tumor–stroma border in
melanoma from ADAM-9/ mice facing a more proliferative
melanoma cell front.
Interestingly, in contrast with our results, using another
melanoma cell line, B16F0, Guaiquil et al. (2009) have
shown that tumor growth of injected cells was reduced in
ADAM-9/ mice compared with controls. One possible
explanation for the difference between our results and those
of Guaiquil and colleagues (2009) is that in their studies the
tumor cells were injected subcutaneously, whereas we used
intradermal injections in our study. This raises the possibility
that the contribution of ADAM-9 to the tumor environment is
dependent on the site. Further studies will be necessary to
confirm the reason for such a discrepancy.
In summary, we have shown in vitro and in vivo that
stromal-derived ADAM-9 is important during the develop-
ment of melanoma, and identified two molecular targets of
ADAM-9 that modulate melanoma cell proliferation and
apoptosis, namely TIMP-1 and TNF-a/sTNFR1.
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MATERIALS AND METHODS
Cells, cell culture, and preparation of CM
Murine dermal fibroblasts were isolated from newborn skin
of WT and ADAM-9/ mice as previously described (Florin et al.,
2006). Isolated fibroblasts, characterized on the basis of their
morphological appearance, were used between passages 2 and
4 for experiments. For the preparation of fibroblast supernatants,
cells were cultured until 90% confluent, washed twice with
phosphate-buffered saline, and cultured with serum-free DMEM
with or without 10 mM TAPI-0 (Biomol, Hamburg, Germany) for
24 hours. The supernatant was centrifuged at 2,000g for 5minutes,
to remove cellular debris, and transferred to new tubes. B16F1
murine melanoma cells were cultured in DMEM containing 10%
fetal calf serum, penicillin, and streptomycin. Further information
including ELISA and antibody array is provided in the Supplementary
Methods online.
Proliferation and apoptosis assays
Cell proliferation was assessed using the Cell Proliferation ELISA kit
(Roche diagnostics, Mannheim, Germany), which measures the
incorporation of BrdU into DNA, according to the manufacturer’s
instructions.
Apoptosis was quantified using cell death detection ELISA (Roche
diagnostics). This assay detects the amount of cytoplasmic oligonu-
cleosomes released after DNA cleavage, using a combination of
anti-histone and anti-DNA capture and detection antibodies.
Recombinant mouse TNF-a (Miltenyi Biotec, Bergisch Gladbach,
Germany) at a concentration of 100 ngml1 was used to induce
cell apoptosis. For neutralization experiments, supernatants were
preincubated with anti-TIMP-1 antibody or IgG control or 5 mgml1
Enbrel (Wyeth Pharma, Mu¨nster, Germany) for 30minutes at room
temperature before stimulating cells.
Tumor growth assay in vivo
B16F1-GFP and B16F0 murine melanoma cells (1 106 cells) in
0.1ml phosphate-buffered saline or transplantable melanoma
cells from Hgf-Cdk4R24C mice were injected intradermally into the
flank of 6- to 8-week old, WT and ADAM-9/ littermate mice as
previously described (Zigrino et al., 2009). These animals are of
mixed genetic background (129/SvJ and C57BL/6J); however, to
reduce variations in the backgroud and to increase the number of
animals needed for the analysis, collected offspring of Adam9/ or
WT from one pair of heterozygous Adam9þ / parents were mated
with one another to generate litters of WT or Adam9/ mice (n¼ 26
for each genotype) that were closely related, as derived from the
same heterozygous grandparents. Tumor size was measured every
2 days using a precision caliper (Mitutoyo, Neuss, Germany), and
volume calculated by multiplying length, width, and depth, which
was expressed as mean±SEM. Animals were killed at day 3, 6,
10, and 13 post injection. The animal experiments were approved
by the local veterinary authority (NRW authorization 50.203.2-K 37a,
20/05).
Immunohistochemistry and immunofluorescence analysis
Tumors were removed surgically at the indicated time point; one half
was embedded in optimal cutting temperature compound (O.C.T,
Vogel, Giessen, Germany) and frozen, and the other half was fixed in
1% formalin and embedded in paraffin. Sections (8mm thick) were cut
and processed for immunofluorescence and immunohistochemistry
analysis. Further information is supplied in the Supplementary Methods
online.
Western blot analysis
CM was concentrated by trichloroacetic acid precipitation and
solubilized in Laemmli sample buffer. Equal amount of proteins were
separated by SDS-PAGE on 10 to 15% (w/v) polyacrylamide gels
under reducing conditions, transferred to a Hybond-C Extra membrane
(Amersham Biosciences, Freiburg, Germany), and incubated with
the primary antibodies overnight at 4 1C. Bound antibodies were
detected with horseradish peroxidase–labeled secondary antibody
(Dako) and enhanced chemiluminuescence (ECL) reaction.
RNA isolation and amplification
Total RNA from tissues was isolated as previously described (Zigrino
et al., 2009). Primers for the amplification of murine ADAM-9, -17,
and S26 were described elsewhere (Zigrino et al., 2009; Mauch
et al., 2010). The primers used for amplification of murine TIMP-1
and TNFRI were as follows: TIMP-1 sense 50-CTGGCATCCT
CTTGTTGCTA-30, antisense 50-AGGGATCTCCAGGTCCACAA-30,
TNFRI sense 50-GGCAGAGGAGCCTAGTTG-30, antisense 50-CACA
CCCAGGAACAGTCC-30. Further information is supplied in the
Supplementary Methods.
Statistical analysis
All experiments were performed at least three times in triplicates
unless otherwise indicated. Statistical analysis of the data was
performed using Student’s t-test. Differences with Po0.05 were
considered statistically significant.
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